Chloroquine-resistant Plasmodium vivax in Papua New Guinea. 1992

G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
Ok Tedi Mining Limited, Medical Department, Western Province, Papua New Guinea.

An Australian expatriate on regular weekly antimalarial prophylaxis with chloroquine base and Maloprim developed symptomatic Plasmodium vivax infection which failed to respond adequately to 600 mg of chloroquine base. More ominously, a resident of the Highlands region of Papua New Guinea contracted vivax malaria which failed to be cleared by 2400 mg chloroquine base administered over 4 d. Both patients had achieved appropriate blood and plasma concentrations of chloroquine after treatment. Chloroquine-resistant P. vivax is now a clinical fact in Papua New Guinea.

UI MeSH Term Description Entries
D008297 Male Males
D010219 Papua New Guinea A country consisting of the eastern half of the island of New Guinea and adjacent islands, including New Britain, New Ireland, the Admiralty Islands, and New Hanover in the Bismarck Archipelago; Bougainville and Buka in the northern Solomon Islands; the D'Entrecasteaux and Trobriand Islands; Woodlark (Murua) Island; and the Louisiade Archipelago. It became independent on September 16, 1975. Formerly, the southern part was the Australian Territory of Papua, and the northern part was the UN Trust Territory of New Guinea, administered by Australia. They were administratively merged in 1949 and named Papua and New Guinea, and renamed Papua New Guinea in 1971. New Guinea, East,New Guinea, Papua
D010966 Plasmodium vivax A protozoan parasite that causes vivax malaria (MALARIA, VIVAX). This species is found almost everywhere malaria is endemic and is the only one that has a range extending into the temperate regions. Plasmodium vivaxs,vivax, Plasmodium
D011739 Pyrimethamine One of the FOLIC ACID ANTAGONISTS that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. Chloridin,Daraprim,Malocide,Tindurine
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D003622 Dapsone A sulfone active against a wide range of bacteria but mainly employed for its actions against MYCOBACTERIUM LEPRAE. Its mechanism of action is probably similar to that of the SULFONAMIDES which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with PYRIMETHAMINE in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) Diaminodiphenylsulfone,Sulfonyldianiline,4,4'-Diaminophenyl Sulfone,Avlosulfone,DADPS,Dapsoderm-X,Dapson-Fatol,Diaphenylsulfone,Disulone,Sulfona,4,4' Diaminophenyl Sulfone,Sulfone, 4,4'-Diaminophenyl
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
September 1980, Papua and New Guinea medical journal,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
January 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
August 1995, The Journal of parasitology,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
September 1976, Papua and New Guinea medical journal,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
October 1994, The Journal of parasitology,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
December 1989, Lancet (London, England),
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
August 1976, The Medical journal of Australia,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
January 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
January 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene,
G J Schuurkamp, and P E Spicer, and R K Kereu, and P K Bulungol, and K H Rieckmann
January 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene,
Copied contents to your clipboard!